Clinical pain conditions may remain responsive to opiate analgesics for extended periods, but such persistent acute pain can undergo a transition to an opiate-resistant chronic pain state that becomes a much more serious clinical problem. To test the hypothesis that cellular mechanisms of chronic pain in the primary afferent also contribute to the development of opiate resistance, we used a recently developed model of the transition of from acute to chronic pain, hyperalgesic priming. Repeated intradermal administration of the potent and highly selective -opioid agonist, [D-Ala 2 ,N-MePhe 4 ,gly-ol]-enkephalin (DAMGO), to produce tolerance for its inhibition of prostaglandin E 2 hyperalgesia, simultaneously produced hyperalgesic priming. Conversely, injection of an inflammogen, carrageenan, used to produce priming produced DAMGO tolerance. Both effects were prevented by inhibition of protein kinase C (PKC). Carrageenan also induced opioid dependence, manifest as -opioid receptor antagonist (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH 2 )-induced hyperalgesia that, like priming, was PKC and G i dependent. These findings suggest that the transition from acute to chronic pain, and development of -opioid receptor tolerance and dependence may be linked by common cellular mechanisms in the primary afferent.